Kuleon LLC
Publicly observedSeattle, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Seattle | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | Kuleon LLC | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | HVKNGYW2QFJ8 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant1 Aug 2025Publicly observed
NIH SBIR/STTR award: Novel and functionally selective 5-HT2C receptor agonist for treating Alcohol Use Disorder
USD 1,002,109.00 · National Institute on Alcohol Abuse and Alcoholism · Source: NIH RePORTER (opens in a new tab)
- Grant1 Aug 2025Publicly observed
NIH SBIR/STTR award: Novel and functionally selective 5-HT2C receptor agonist for treating Alcohol Use Disorder
USD 1,001,425.00 · National Institute on Alcohol Abuse and Alcoholism · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.